Abeona Therapeutics Inc. (ABEO) vs Standard BioTools Inc. (LAB)

A side-by-side comparison of Abeona Therapeutics Inc. and Standard BioTools Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare

Total return — ABEO vs LAB

growth of $100 · dividends reinvested · last 10y
ABEO -96.6% (-28.7%/yr)LAB -90.2% (-20.7%/yr)LAB compounded faster over this window
0100200300Start $10020182020202220242026$3$10
ABEO LAB

ABEO vs LAB: by the numbers

  • •ABEO is the larger company ($286M vs $283M market cap).
  • •Both run net losses; LAB's is the smaller (-103.29% vs -246.42% net margin).
  • •Both shrank revenue over the past five years; ABEO's decline was smaller (-10.26% vs -10.62% CAGR).

Metrics side by side

Valuation

MetricABEOLAB
P/S ratio11.193.34
P/B ratio2.230.52

Profitability

MetricABEOLAB
Gross margin73.68%49.14%
Operating margin-1536.91%-109.34%
Net margin-246.42%-103.29%
ROE-49.11%-16.18%
ROIC-49.76%-14.06%

Growth (annualized)

MetricABEOLAB
Revenue CAGR (5Y)-10.26%-10.62%
Total return CAGR (5Y)-26.46%-32.98%

Frequently asked

Which has grown faster, ABEO or LAB?
Neither grew: over the past five years both shrank revenue, with ABEO's decline the smaller — ABEO at a -10.26% CAGR versus LAB at -10.62%.
How have ABEO and LAB total returns compared?
Over the past 10 years, ABEO delivered -29.45% and LAB delivered -20.93% annualized total return. Past performance doesn't predict future results.

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.